MO-PIERIANDX
14.10.2020 14:02:03 CEST | Business Wire | Press release
PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology company, today announced a partnership that enables Pillar Biosciences to sell directly the PierianDx clinical genomic report in combination with its cancer profiling assays. Under the agreement, PierianDx will integrate the Pillar Biosciences PiVAT® bioinformatics pipeline in the PierianDx environment to provide users with an accelerated implementation, including assay-specific variant filters, to produce best-in-class clinical genomics reports and enable a complete sample-to-answer solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201014005056/en/
Laboratories worldwide use Pillar Biosciences’ assays to detect pivotal genetic variants for cancer and other diseases. Pillar Biosciences’ targeted panels utilize a proprietary enrichment chemistry, SLIMamp®, that enables rapid, automated amplification of overlapping amplicons in a single tube using minimal sample inputs. Pillar Biosciences’ complementary bioinformatics pipeline, PiVAT® , is optimized for efficiency, reducing reflex testing and enabling low-frequency variant calling for every type of variant while consuming limited computing resources. PierianDx provides the Clinical Genomics Workspace™, which consists of intuitive software and a robust clinical Knowledgebase that transforms variant information into a highly-structured and comprehensive physician-ready report.
Streamlining NGS along with clinical genomic interpretation and reporting, especially for sophisticated panels, remains time-consuming and challenging. By packaging the Pillar Biosciences panels with the PierianDx report, the result will be an out-of-the-box clinical genomic report that is optimized for each assay. Furthermore, the solution will be available to customers globally through secure, and in the case of European regions, Global Data Protection Regulation (GDPR)-compliant, cloud instances. As a result, laboratories and healthcare organizations worldwide will have a highly reliable method for providing these tests to enable precision diagnostics and treatments for their patients.
“The assays from Pillar Biosciences provide robust detection for all variant types in a simplified workflow,” states Gang Song, PhD, CEO of Pillar Biosciences. “By optimizing variant filters and integrating with the PiVAT pipeline, PierianDx is streamlining interpretation and reporting, which adds substantial value for our customers.”
Rakesh Nagarajan, MD, PhD and Founder and Chief Technical and Visionary Officer of PierianDx, adds, “We are thrilled to provide this support for the Pillar Biosciences assays. As the market shifts to more sensitive assays in the LDT space and leading assay manufacturers seek in vitro diagnostic (IVD) approval, we are committed to addressing challenges that arise from even greater complexity in the interpretation and reporting process.”
About PierianDx
Founded in 2014 out of Washington University in St. Louis, PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Its industry-leading clinical genomics technologies, CAP and CLIA accredited laboratory, IVD-ready knowledgebase and reporting solution, and expertise deliver the most integrated, trusted, and collaborative approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx drives the adoption of genomics in clinical care and accelerates the fight against somatic cancer and hereditary germline diseases. www.pieriandx.com .
About Pillar Biosciences
Pillar Biosciences is a clinical cancer diagnostics company based in Boston, Massachusetts and Shanghai, China. Our automatable variant detection technologies deliver robust results with rapid turnaround times through streamlined NGS workflows. Our SLIMamp® – and PiVAT® -based products help high-throughput reference laboratories and clinical oncology laboratories make precision medicine practical by boosting their diagnostic productivity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005056/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lyft App Launches in Europe30.9.2026 14:00:00 CEST | Press release
North American riders can use their Lyft app when traveling in Europe Key takeaways: North American Lyft riders can now use one app in the U.S., Canada, and Europe. No need to download anything new. New technology allows the Lyft app to integrate any third-party marketplace, laying the groundwork for future international growth. Lyft has transformed from an everyday rideshare company into a global, multi-mobility platform. Starting today, Lyft (NASDAQ: LYFT) riders can use their Lyft app in cities across Europe. Early access to the Lyft app rolls out in Barcelona and Hamburg first; throughout October, the Lyft app will become available for riders to use in some of Europe’s largest cities including London, Rome, Paris, Berlin, Athens, and Warsaw. By the end of October riders visiting Spain, Italy, Greece, Poland, England, Scotland, Ireland, Austria, France, and Germany will have one go-to app when they cross the Atlantic, building on the foundations from this past summer beta testing th
A Workplace Worth Toasting: Bacardi Continues its Rise on Forbes World’s Best Employers List30.9.2026 13:45:00 CEST | Press release
Bacardi Takes Top Spot Among Spirits Companies with Jump to #69 Bacardi Limited is proving that a workplace worth toasting keeps getting better. The family-owned business has once again been named to the Forbes World's Best Employers list, taking the top spot among spirits companies. Climbing 17 places since last year, in 2026 Bacardi comes in at #69 globally. The jump in ranking reflects a commitment to creating a workplace where employees feel valued, empowered, and inspired to grow while helping shape the future of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930327935/en/ Bacardi Limited Leads Spirits Companies Forbes World's Best Employers 2026 Ranking. “At Bacardi, great moments start with great people. That's why we listen carefully to what they're telling us, learn from that feedback, and keep evolving. We want people to feel clear on how they can grow, confident they can make their mark, and suppor
Forrester’s 2027 European Predictions: Despite A Strong Desire To Regain Its Digital Sovereignty, Europe Will Selectively Reset, Not Sever, Key Technology Relationships30.9.2026 13:33:00 CEST | Press release
New AI sovereignty and platform governance rules will signal strategic intent but deliver limited near-term impact According to Forrester’s (Nasdaq: FORR) 2027 European predictions, unveiled today at Forrester’s Technology & Innovation Forum EMEA, Europe will enter 2027 determined to recover its digital autonomy, but the gap between its ambition and control will widen. More than half of European companies embracing AI will reduce their dependence on US hyperscalers due to sovereignty concerns, moving their critical data and applications to European providers. A lack of end-to-end sovereign alternatives, however, will require consumers, companies, and policymakers to pursue selective digital autonomy, which consequently will reshape consumer behaviours, cloud choices, mobility, resilience, and trade strategy with China. Forrester’s Predictions reports offer forward-looking insights into trends to help executives and their teams anticipate change, reduce uncertainty, and make confident d
Vasion® Named a Leader in the 2026 IDC MarketScape for Worldwide Print Management Solutions as Enterprise Print Becomes AI Ready30.9.2026 13:30:00 CEST | Press release
Vasion, the intelligent print automation company, today announced it has been named a Leader in the IDC MarketScape for Worldwide Print Management Solutions 2026 Vendor Assessment (doc # US54124826, September 2026). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930788016/en/ According to the IDC MarketScape, "Organizations in sectors such as education, healthcare, government, manufacturing, financial services, and retail should consider Vasion when seeking support for business process automation revolving around print, output, and agentic or rules-based workflows. Vasion customers may derive considerable value from the vendor's solutions in support of unifying their organizations' digital transformation efforts, particularly where a single portal with functionality extending beyond print management is sought, and especially where FedRAMP® High Authorization, a SOC 2 Type II report, or ISO 27001/42001 certification is req
Pantheon Expands Middle East Presence With New Abu Dhabi Office and Senior Regional Appointment30.9.2026 12:56:00 CEST | Press release
Abu Dhabi office, based in ADGM, continues Pantheon’s global expansion to serve growing client demand in key markets such as the Middle EastFiras Mallah joins as Managing Director and Head of Middle East to lead capital formation with sovereign wealth funds, family offices, and financial institutions across the region Pantheon, a leading global private markets firm with approximately $84bn in assets under management, today announced the expansion of its presence in the Middle East with the opening of its first office in ADGM, the international financial center based in Abu Dhabi, alongside the appointment of Firas Mallah as Managing Director and Head of Middle East. Demand for access to private equity, infrastructure, and private credit strategies continues to build among sophisticated investors across the Middle East, who recognize Pantheon for its 40-year track record of innovation and expertise across primaries, secondaries and co-investment opportunities. Secondaries – pioneered by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom